Toll Free Helpline (India): 1800 1234 070
Rest of World: +91-9810852116
Free Publication Certificate
Submit Manuscript
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
Vol. 7, Issue 5 (2018)
Influence of the course of stabilization of chronic obstructive pulmonary disease with bronchial obstruction of the ii degree in basic tiotropium bromide treatment on the dynamics of TNFa, INFg, IL-4, IL-6 levels and lung surfactant system
Author(s):
ММ Ostrovskyi, МО Kulynych-Miskiv and ІО Savelikhina
ММ Ostrovskyi, МО Kulynych-Miskiv and ІО Savelikhina
Abstract:
The researchworkrepresents data on pathogenetic characteristics of immune response, tumour necrosis factor-α (TNFα), interferon-g (INFg), interleukin-4 (IL-4), interleukin-6 (IL-6) and lung surfactant system (LSS) in the process of treatment of chronic obstructive pulmonary disease. Administrationof tiotropium bromide (Spiriva ® "Boehringer Ingelheim") in comprehensive treatment of chronic obstructive pulmonary disease withbronchial obstruction of the II degree promotes faster regression of clinical and laboratory symptoms, leading to the decrease of TNFα and IL-6 levels, as compared to patients receiving traditional therapy. Theuseof tiotropium bromide ensuresmoreadequaterestorationofIL-4 andINFglevelsinbronchoalveolar fluid in patients suffering from COPD with bronchial obstruction of the II degree. Ithasbeenestablishedthattherestorationofsurface-activefractionofLSSwasmuchbetterinpatientsreceiving tiotropium bromide aspartoftheircomprehensivetreatment, which clearly correlates with the prolongation of drug administration.
The researchworkrepresents data on pathogenetic characteristics of immune response, tumour necrosis factor-α (TNFα), interferon-g (INFg), interleukin-4 (IL-4), interleukin-6 (IL-6) and lung surfactant system (LSS) in the process of treatment of chronic obstructive pulmonary disease. Administrationof tiotropium bromide (Spiriva ® "Boehringer Ingelheim") in comprehensive treatment of chronic obstructive pulmonary disease withbronchial obstruction of the II degree promotes faster regression of clinical and laboratory symptoms, leading to the decrease of TNFα and IL-6 levels, as compared to patients receiving traditional therapy. Theuseof tiotropium bromide ensuresmoreadequaterestorationofIL-4 andINFglevelsinbronchoalveolar fluid in patients suffering from COPD with bronchial obstruction of the II degree. Ithasbeenestablishedthattherestorationofsurface-activefractionofLSSwasmuchbetterinpatientsreceiving tiotropium bromide aspartoftheircomprehensivetreatment, which clearly correlates with the prolongation of drug administration.
Pages: 616-618 | 573 Views 84 Downloads
How to cite this article:
ММ Ostrovskyi, МО Kulynych-Miskiv, ІО Savelikhina. Influence of the course of stabilization of chronic obstructive pulmonary disease with bronchial obstruction of the ii degree in basic tiotropium bromide treatment on the dynamics of TNFa, INFg, IL-4, IL-6 levels and lung surfactant system . Pharma Innovation 2018;7(5):616-618.
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
The Pharma Innovation Journal
